Patents by Inventor Kunio Sugahara

Kunio Sugahara has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20150335656
    Abstract: The invention provides a method of inhibiting binding between acetylated histone and a bromodomain-containing protein in a mammal, as well as a method of shrinking or killing of cancer cells expressing a bromodomain-containing protein or inhibiting the growth of cancer cells expressing a bromodomain-containing protein in a mammal. The methods involve administering an effective amount of (S)-2-[4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl]-N-(4-hydroxyphenyl)acetamide or a dihydrate thereof to the mammal.
    Type: Application
    Filed: August 5, 2015
    Publication date: November 26, 2015
    Inventors: Shinji MIYOSHI, Shinsuke OOIKE, Kazunori IWATA, Hidemasa HIKAWA, Kunio SUGAHARA
  • Patent number: 9125915
    Abstract: The invention provides a method of inhibiting binding between acetylated histone and a bromodomain-containing protein in a mammal, as well as a method of shrinking or killing of cancer cells expressing a bromodomain-containing protein or inhibiting the growth of cancer cells expressing a bromodomain-containing protein in a mammal. The methods involve administering an effective amount of (S)-2-[4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl]-N-(4-hydroxyphenyl)acetamide or a dihydrate thereof to the mammal.
    Type: Grant
    Filed: May 28, 2013
    Date of Patent: September 8, 2015
    Assignee: Mitsubishi Tanabe Pharma Corporation
    Inventors: Shinji Miyoshi, Shinsuke Ooike, Kazunori Iwata, Hidemasa Hikawa, Kunio Sugahara
  • Patent number: 8809304
    Abstract: A novel amine compound represented by the following formula (I), which is superior in immunosuppressive action, rejection suppressive action and the like, and shows reduced side effects such as bradycardia and the like, or a pharmaceutically acceptable acid addition salt thereof, or hydrates thereof, or solvate, as well as a pharmaceutical composition containing this compound and a pharmaceutically acceptable carrier. wherein R is a hydrogen atom or P(?O)(OH)2, X is an oxygen atom or a sulfur atom, Y is CH2CH2 or CH?CH, R1 is cyano or alkyl having a carbon number of 1 to 4 and substituted by a halogen atom(s), R2 is alkyl having a carbon number of 1 to 4 and optionally substituted by a hydroxyl group(s) or a halogen atom(s), R3 and R4 may be the same or different and each is a hydrogen atom or alkyl having a carbon number of 1 to 4, and n is 5-8.
    Type: Grant
    Filed: December 15, 2006
    Date of Patent: August 19, 2014
    Assignee: Mitsubishi Tanabe Pharma Corporation
    Inventors: Masatoshi Kiuchi, Kaoru Marukawa, Nobutaka Kobayashi, Kunio Sugahara
  • Publication number: 20130261109
    Abstract: The invention provides a method of inhibiting binding between acetylated histone and a bromodomain-containing protein in a mammal, as well as a method of shrinking or killing of cancer cells expressing a bromodomain-containing protein or inhibiting the growth of cancer cells expressing a bromodomain-containing protein in a mammal. The methods involve administering an effective amount of (S)-2-[4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl]-N-(4-hydroxyphenyl)acetamide or a dihydrate thereof to the mammal.
    Type: Application
    Filed: May 28, 2013
    Publication date: October 3, 2013
    Inventors: Shinji MIYOSHI, Shinsuke OOIKE, Kazunori IWATA, Hidemasa HIKAWA, Kunio SUGAHARA
  • Patent number: 8476260
    Abstract: The present invention relates to a novel antitumor agent containing a compound that inhibits binding between acetylated histone and a bromodomain-containing protein, preferably a thienotriazolodiazepine compound represented by the following formula (I) wherein each symbol is as defined in the description, or a pharmaceutically acceptable salt thereof or a hydrate or solvate as an active ingredient.
    Type: Grant
    Filed: December 26, 2008
    Date of Patent: July 2, 2013
    Assignee: Mitsubishi Tanabe Pharma Corporation
    Inventors: Shinji Miyoshi, Shinsuke Ooike, Kazunori Iwata, Hidemasa Hikawa, Kunio Sugahara
  • Patent number: 8129361
    Abstract: Provided is a novel amine compound represented by the following formula (I) having a superior peripheral blood lymphocyte decreasing action and superior in the immunosuppressive action, rejection suppressive action and the like, which shows decreased side effects of, for example, bradycardia and the like, or a pharmaceutically acceptable acid addition salt thereof, or a hydrate thereof, or a solvate thereof. wherein each symbol is as defined in the specification.
    Type: Grant
    Filed: June 13, 2008
    Date of Patent: March 6, 2012
    Assignee: Mitsubishi Tanabe Pharma Corporation
    Inventors: Masatoshi Kiuchi, Kaoru Tashiro, Maiko Hamada, Kunio Sugahara
  • Patent number: 8114902
    Abstract: Disclosed is a 2-aminobutanol compound represented by the following formula (I) or a pharmaceutically acceptable acid addition salt thereof, or a hydrate thereof, or a solvate thereof, as well as a production method of the 2-aminobutanol compound of formula (I). The 2-aminobutanol compounds of formula (I) have few side effects including bradycardia and have superior peripheral blood lymphocyte-decreasing effects.
    Type: Grant
    Filed: April 27, 2007
    Date of Patent: February 14, 2012
    Assignee: Mitsubishi Tanabe Pharma Corporation
    Inventors: Masatoshi Kiuchi, Mitsuharu Nakamura, Maiko Hamada, Kunio Sugahara
  • Patent number: 8044042
    Abstract: A thienotriazolodiazepine compound of the following formula (I) a pharmaceutical agent containing the compound as an active ingredient, and a production intermediate and a production method of the thienotriazolodiazepine compound. Since this compound has an inhibitory action on costimulatory signal from CD28 on T cell, it is useful for the prophylaxis or suppression of rejection reaction in transplantation of organ or bone marrow and the like, and the prophylaxis or treatment of autoimmune diseases or allergic diseases.
    Type: Grant
    Filed: May 30, 2006
    Date of Patent: October 25, 2011
    Assignee: Mitsubishi Tanabe Pharma Corporation
    Inventors: Kunitomo Adachi, Hidemasa Hikawa, Maiko Hamada, Jun-ichi Endoh, Seigo Ishibuchi, Naoto Fujie, Minoru Tanaka, Kunio Sugahara, Kouichi Oshita, Meguru Murata
  • Publication number: 20100286127
    Abstract: The present invention relates to a novel antitumor agent containing a compound that inhibits binding between acetylated histone and a bromodomain-containing protein, preferably a thienotriazolodiazepine compound represented by the following formula (I) wherein each symbol is as defined in the description, or a pharmaceutically acceptable salt thereof or a hydrate or solvate as an active ingredient.
    Type: Application
    Filed: December 26, 2008
    Publication date: November 11, 2010
    Applicant: MITSUBISHI TANABE PHARMA CORPORATION
    Inventors: Shinji Miyoshi, Shinsuke Ooike, Kazunori Iwata, Hidemasa Hikawa, Kunio Sugahara
  • Publication number: 20100179216
    Abstract: Provided is a novel amine compound represented by the following formula (I) having a superior peripheral blood lymphocyte decreasing action and superior in the immunosuppressive action, rejection suppressive action and the like, which shows decreased side effects of, for example, bradycardia and the like, or a pharmaceutically acceptable acid addition salt thereof, or a hydrate thereof, or a solvate thereof. wherein each symbol is as defined in the specification.
    Type: Application
    Filed: June 13, 2008
    Publication date: July 15, 2010
    Inventors: Masatoshi Kiuchi, Kaoru Tashiro, Maiko Hamada, Kunio Sugahara
  • Publication number: 20100041643
    Abstract: [Solving means] A thienotriazolodiazepine compound of the following formula (I) a pharmaceutical agent containing the compound as an active ingredient, and a production intermediate and a production method of the thienotriazolodiazepine compound. [Effect]Since this compound has an inhibitory action on costimulatory signal from CD28 on T cell, it is useful for the prophylaxis or suppression of rejection reaction in transplantation of organ or bone marrow and the like, and the prophylaxis or treatment of autoimmune diseases or allergic diseases.
    Type: Application
    Filed: May 30, 2006
    Publication date: February 18, 2010
    Applicant: MITSUBISHI TANABE PHARMA CORPORATION
    Inventors: Kunitomo Adachi, Hidemasa Hikawa, Maiko Hamada, Jun-ichi Endoh, Seigo Ishibuchi, Naoto Fujie, Minoru Tanaka, Kunio Sugahara, Kouichi Oshita, Meguru Murata
  • Publication number: 20090137530
    Abstract: A novel amine compound represented by the following formula (I), which is superior in immunosuppressive action, rejection suppressive action and the like, and shows reduced side effects such as bradycardia and the like, or a pharmaceutically acceptable acid addition salt thereof, or hydrates thereof, or solvate, as well as a pharmaceutical composition containing this compound and a pharmaceutically acceptable carrier. wherein R is a hydrogen atom or P(?O)(OH)2, X is an oxygen atom or a sulfur atom, Y is CH2CH2 or CH?CH, R1 is cyano or alkyl having a carbon number of 1 to 4 and substituted by a halogen atom(s), R2 is alkyl having a carbon number of 1 to 4 and optionally substituted by a hydroxyl group(s) or a halogen atom(s), R3 and R4 may be the same or different and each is a hydrogen atom or alkyl having a carbon number of 1 to 4, and n is 5-8.
    Type: Application
    Filed: December 15, 2006
    Publication date: May 28, 2009
    Applicant: Mitsubishi Tanabe Pharma Corporation
    Inventors: Masatoshi Kiuchi, Kaoru Marukawa, Nobutaka Kobayashi, Kunio Sugahara
  • Publication number: 20090082311
    Abstract: The present invention provides a novel compound having few side effects such as bradycardia and the like and having superior peripheral blood lymphocyte-decreasing effect.
    Type: Application
    Filed: April 27, 2007
    Publication date: March 26, 2009
    Applicant: Mitsubishi Tanabe Pharma Corporation
    Inventors: Masatoshi Kiuchi, Mitsuharu Nakamura, Maiko Hamada, Kunio Sugahara
  • Patent number: 6288061
    Abstract: The present invention relates to the imidazole derivative of the following formula (I) wherein R1 is hydrogen, optionally substituted alkyl and the like, R2 is hydrogen, optionally substituted alkyl and the like, R3is optionally substituted heteroaryl, R4 is optionally substituted cycloalkyl, optionally substituted phenyl and the like, provided that when R1 is hydrogen, and R2 and R4 are the same or different and each is phenyl or phenyl substituted by halogen atom, lower alkyl or lower alkoxy, R3 is benzothiazolyl or thiazolyl substituted by phenyl, the imidazole derivative of the following formula (XII) wherein R6 is optionally substituted phenyl or optionally substituted heteroaryl and R7 is substituted phenyl, and pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: June 21, 2000
    Date of Patent: September 11, 2001
    Assignee: Welfide Corporation
    Inventors: Hiroyuki Sueoka, Jouji Yasuoka, Akira Nishiyama, Masatoshi Kiuchi, Katsuya Yamamoto, Kunio Sugahara, Syuji Ehara, Kei Sakata